secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coherus Oncology, Inc. (CHRS)
CIK:        0001512762
Form:       8-K
Filed at:   2026-01-13T23:59:59+00:00
Accession:  0001104659-26-003117
Event type: other_material
Sentiment:  neutral
Materiality: 0.25
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Coherus Oncology provides preliminary FY2025 revenue and cash at J.P. Morgan conference
--------------------------------------------------------------------------------

- Filing furnishes preliminary unaudited net revenues for Q4 and FY2025 ended Dec 31, 2025.
- Preliminary cash, cash equivalents and investments as of Dec 31, 2025 also disclosed.
- Slide includes forward-looking projection of LOQTORZI revenue growth.
- Actual final results may differ materially; independent auditor has not reviewed these preliminary figures.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1512762/000110465926003117/0001104659-26-003117-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1512762/000110465926003117/chrs-20260113x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-003117

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer